 Connection
Myron Levin to Neuralgia, Postherpetic
This is a "connection" page, showing publications Myron Levin has written about Neuralgia, Postherpetic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.563 |
|
|
|
-
Levin MJ, Gershon AA, Dworkin RH, Brisson M, Stanberry L. Prevention strategies for herpes zoster and post-herpetic neuralgia. J Clin Virol. 2010 May; 48 Suppl 1:S14-9.
Score: 0.341
-
Brisson M, Pellissier JM, Levin MJ. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis. 2007 Dec 01; 45(11):1527-9.
Score: 0.288
-
Johnson R, McElhaney J, Pedalino B, Levin M. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis. 2007 Nov; 11 Suppl 2:S43-8.
Score: 0.287
-
Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007 Nov 28; 25(49):8326-37.
Score: 0.286
-
Levin MJ, Schmader K. Prevention strategies: herpes zoster, post-herpetic neuralgia and immunogenicity. Herpes. 2007 Sep; 14 Suppl 2:45-7.
Score: 0.283
-
Oostvogels L, Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P, Zahaf T, Dagnew AF, Chlibek R, Diez-Domingo J, Gorfinkel IS, Herv? C, Hwang SJ, Ikematsu H, Kalema G, Lal H, McNeil SA, Mrkvan T, Pauksens K, Smetana J, Watanabe D, Weckx LY, Cunningham AL. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vaccin Immunother. 2019; 15(12):2865-2872.
Score: 0.161
-
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, D?ez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barber? J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016 Sep 15; 375(11):1019-32.
Score: 0.133
-
Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M. Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother. 2013 May; 9(5):1177-84.
Score: 0.103
-
Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, Fournier SO, Mansi JA, Brisson M. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine. 2012 Mar 09; 30(12):2047-50.
Score: 0.096
-
Benbernou A, Drolet M, Levin MJ, Schmader KE, Oxman MN, Johnson R, Patrick D, Camden S, Mansi JA, Brisson M. Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. Eur J Pain. 2011 Nov; 15(10):1100-6.
Score: 0.092
-
Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, Patrick D, Camden S, Mansi JA. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain. 2010 Nov; 11(11):1211-21.
Score: 0.088
-
Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010 Nov 09; 182(16):1731-6.
Score: 0.088
-
Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, Levin MJ, Schmader KE, Gelb LD, Keay S, Neuzil K, Greenberg RN, Griffin MR, Davis LE, Morrison VA, Annunziato PW. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010 May 04; 152(9):545-54.
Score: 0.085
-
Oxman MN, Levin MJ. Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis. 2008 Mar 01; 197 Suppl 2:S228-36.
Score: 0.073
-
Gershon AA, Arvin AM, Levin MJ, Seward JF, Schmid DS. Varicella vaccine in the United States: a decade of prevention and the way forward. J Infect Dis. 2008 Mar 01; 197 Suppl 2:S39-40.
Score: 0.073
-
Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, Volpi A, Heineman TC. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018 03 14; 36(12):1537-1541.
Score: 0.037
-
Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman CA, Marques A, Toney J, Boardman K, Su SC, Li X, Chan IS, Parrino J, Annunziato P, Oxman MN. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015 Mar 15; 60(6):900-9.
Score: 0.029
-
Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Sch?del F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009 Oct 01; 200(7):1068-77.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|